AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 10 - (NewsRx.com & NewsRx.net) --
La Jolla Pharmaceutical Company announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase I/II clinical trial of LJP 1082, its clinical candidate for the treatment of antibody-mediated thrombosis, a life-threatening blood-clotting disorder.
"The successful filing of an IND for our second clinical candidate represents a major milestone. We now have two clinical candidates based on our proprietary Tolerance Technology approach," said Steven B. Engle, La Jolla Pharmaceutical Company. "Like our Phase III drug candidate for lupus, LJP 1082 is designed to reduce the production of disease-causing antibodies without affecting the disease-fighting ability of the immune system. LJP 1082 represents the first specific therapy to focus on the cause of this disease."
LJP has presented positive preclinical results demonstrating that LJP 1082 reduces disease-causing antibodies and the related B cells in several animal models. These studies also confirmed the impact of the targeted autoantibodies on a key clot-promoting coagulation factor, Factor Va. These results were presented at the ...
Source: HighBeam Research, Trial Initiated Against Antibody-Mediated Stroke And Deep-Vein...